Rosiglitazone Associated with Increased Risk for MI

Thiazolidinediones are peroxisome-proliferator–activated receptor-γ agonists that increase insulin sensitivity in the peripheral tissues; their FDA approval was largely based on their ability to lower blood glucose levels. Rosiglitazone (Avandia), one of two approved thiazolidinediones, was introduced in 1999 and is used by many patients with diabetes to control blood glucose levels. A third thiazolidinedione, muraglitazar, was not approved for market because of concerns about an increase in cardiovascular events, and another, troglitazone, was removed from the market because of liver toxicity. To assess rosiglitazone’s effect on CV outcomes, investigators performed a meta-analysis of published and unpublished randomized studies posted on a…